Compare Ginkgo Bioworks Holdings Inc (DNA) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs LTC Properties Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.87 (market cap $772.39M), while LTC Properties Inc trades at $43.29 (market cap $2.25B). The key difference: LTC Properties Inc is far larger — about 2.9× Ginkgo Bioworks Holdings Inc's market cap, and LTC Properties Inc pays a 5.45% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and LTC Properties Inc for 89 Days on average.
| DNA | LTC | |
|---|---|---|
Market Cap | $772.39M | $2.25B |
Volume | 6,453,273 | 1,238,557 |
Sector | Health | Real Estate |
52-Week High | $15.83 | $43.50 |
52-Week Low | $5.48 | $33.98 |
Typical Hold Time | 7 Days | 89 Days |
Enterprise Value | $874.34M | $2.99B |
Dividend Yield | — | 5.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
LTC Properties trades at $41.81, down 1.48% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The REIT maintains strong profitability with 38.93% net margins and pays consistent monthly dividends of $0.19 per share. Recent acquisitions totaling $360 million accelerate the company's SHOP portfolio transformation, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with demographic tailwinds in senior housing but faces execution risks from aggressive expansion. The stock trades at reasonable valuations (P/E 14.93) with upside to analyst targets, though rising interest rates and integration challenges warrant caution for the growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
